CA
NZ
UK
AU
IND
US
Collaboration revenue reached an all-time high of USD 2.7 billion, including USD 2.6 billion from the company's share of collaboration profits. That share rose 77% on continued Dupixent sales growth and completion of the Sanofi development balance repayment in the second quarter, so the …
Nine-month net income was USD 36.3 million, or USD 5.49 per share, up 15.8% from USD 31.3 million, or USD 4.65. Return on assets for the period was 1.45% and return on equity was 12.73%.
The effective income tax rate for the three and nine months was zero. The third-quarter loss was roughly 5.4 times the prior-year figure and the nine-month loss roughly 5.7 times, and the increase in the accumulated deficit since year end equals the nine-month net …
The company said strongOperating Cash Flowlet it surpass its year-end leverage target, reaching 1.8x.
Other income, net rose USD 1.1 million to USD 4.1 million from USD 3.0 million, and the income tax provision rose USD 32 thousand. The net loss rose about 17% in the quarter, general and administrative expense rose about 29%, employee compensation about 17%, …
Management said 85% of new U.S. product launches in the quarter were naturally colored, and that FDA synthetic color certifications fell nearly 10% over twelve months as customers replace synthetic colors. Customers are destocking synthetic colors across their portfolios, and management anticipates a continued …
Management cited a capacity shift from landing gear to the higher-margin APU business, healthy trading activity, the addition of distribution and operational efficiency initiatives. Chief executive Igal Zamir said the APUBusinessgrew on new contracts won this year and improvedSupplychain,Demandis robust across APUs and heat …
The company generated adjusted EBITDA of USD 25.6 million and ended the quarter with USD 854 million in cash and marketable securities. Management saidGross Profitdollar growth outpaced investment, allowing theBusinessto turn the corner on EBITDA.
Nine-month electric operating revenues were USD 1,786.8 million versus USD 1,632.4 million, and nine-month net earnings attributable were USD 238.4 million, or USD 2.15 per diluted share, versus USD 161.2 million, or USD 1.63.
General and administrative expenses were USD 23.9 million versus USD 14.0 million. The increase in stock-based compensation was primarily driven by grants to new management team members hired in the second and third quarters of 2025, an appreciation in the stock price and incremental …
Please wait processing your request...